DURECT Stock Forecast, Price & News

DURECT (NASDAQ:DRRX) Frequently Asked Questions

Is DURECT a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DURECT stock.
View analyst ratings for DURECT or view top-rated stocks.

How has DURECT's stock price been impacted by COVID-19 (Coronavirus)?

DURECT's stock was trading at $1.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRRX shares have decreased by 38.2% and is now trading at $1.02.
View which stocks have been most impacted by COVID-19.

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for DURECT.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Monday, November, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.01. The specialty pharmaceutical company had revenue of $2.17 million for the quarter, compared to analyst estimates of $2.18 million. DURECT had a negative trailing twelve-month return on equity of 58.72% and a negative net margin of 280.15%. During the same quarter in the prior year, the business earned ($0.05) EPS.
View DURECT's earnings history.

What price target have analysts set for DRRX?

3 brokerages have issued twelve-month price objectives for DURECT's shares. Their forecasts range from $6.00 to $8.00. On average, they expect DURECT's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 586.3% from the stock's current price.
View analysts' price targets for DURECT or view top-rated stocks among Wall Street analysts.

Who are DURECT's key executives?

DURECT's management team includes the following people:

• James E. Brown, President, Chief Executive Officer & Director
• Judy R. Joice, Senior VP-Operations & Corporate Quality Assurance
• Michael H. Arenberg, Chief Financial Officer & Secretary
• Wei Qi Lin, Executive Vice President-Research & Development
• David J. Ellis, Vice President-Clinical Development

Who are some of DURECT's key competitors?

Some companies that are related to DURECT include Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), RAPT Therapeutics (RAPT), IDEAYA Biosciences (IDYA), Zymeworks (ZYME), Tango Therapeutics (TNGX), BELLUS Health (BLUSF), Seres Therapeutics (MCRB), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Olema Pharmaceuticals (OLMA), Arcutis Biotherapeutics (ARQT), Kinnate Biopharma (KNTE) and ADVANZ PHARMA (CXRXF).
View all of DRRX's competitors.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by many different institutional and retail investors. Top institutional shareholders include Lion Point Capital LP (6.81%), BlackRock Inc. (6.30%), Ingalls & Snyder LLC (3.21%), Geode Capital Management LLC (1.70%), Renaissance Technologies LLC (1.31%) and Beirne Wealth Consulting Services LLC (1.04%). Company insiders that own DURECT stock include Judy R Joice and Lp Bleichroeder.
View institutional ownership trends for DURECT.

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Millennium Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Ingalls & Snyder LLC, Goldman Sachs Group Inc., The Manufacturers Life Insurance Company , and Citadel Advisors LLC.
View insider buying and selling activity for DURECT or view top insider-selling stocks.

Which institutional investors are buying DURECT stock?

DRRX stock was purchased by a variety of institutional investors in the last quarter, including Healthcare Value Capital LLC, Lion Point Capital LP, Kings Point Capital Management, Beirne Wealth Consulting Services LLC, Geode Capital Management LLC, Barclays PLC, SG Americas Securities LLC, and GSA Capital Partners LLP.
View insider buying and selling activity for DURECT or or view top insider-buying stocks.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.02.

How much money does DURECT make?

DURECT has a market capitalization of $232.06 million and generates $30.11 million in revenue each year. The specialty pharmaceutical company earns $-580 thousand in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does DURECT have?

DURECT employs 81 workers across the globe.

What is DURECT's official website?

The official website for DURECT is www.durect.com.

Where are DURECT's headquarters?

DURECT is headquartered at 10260 BUBB RD, CUPERTINO CA, 95014.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at [email protected], or via fax at 408-777-3577.